AimedBio announced on February 3 that it has entered into a joint research agreement with AIVIS, an AI-based digital pathology company, and completed a strategic equity investment (SI) to strengthen its antibody–drug conjugate (ADC) drug development capabilities. The size of the investment was not disclosed.

Founded in January 2021, AIVIS provides AI-powered solutions that quantitatively analyze biomarker expression from digital pathology images to support clinical decision-making. The company was founded by a research team specializing in image processing and artificial intelligence at Korea University, led by CEO Daehong Lee, and includes Gyuyeong Kim, MD, former pathologist at Samsung Medical Center, as Chief Medical Officer (CMO).

Through this collaboration, AimedBio will leverage AIVIS’s Qanti Discovery platform to apply AI-based quantitative analysis to pathology data generated during ADC development. The partnership aims to enhance the probability of clinical success by establishing biomarker-driven patient selection strategies.

AimedBio plans to advance the collaboration in stages, focusing on automation of non-clinical and clinical pathology data analysis, improvement of patient selection precision, and development of an AI-based companion diagnostics (CDx) strategy.

An AimedBio representative stated,

“In the era of ADCs, AI-driven digital pathology and biomarker quantification capabilities are critical differentiators. Through this partnership, we aim to strengthen our data-driven drug development framework and enhance our clinical development competitiveness.”

Qanti IHC, an AI-based medical device developed by AIVIS, enables cell-level quantitative analysis of IHC-stained slides. In September 2024, it received in vitro diagnostic medical device approval from Korea’s Ministry of Food and Drug Safety (MFDS). The solution is currently deployed in more than 10 major hospitals in Korea to support pathologists in improving diagnostic accuracy.

AIVIS has continued to expand its strategic collaborations, including a licensing agreement with Philips Korea for AI-based cancer biomarker quantification solutions, as well as a memorandum of understanding (MOU) with AstraZeneca Korea last year to support the development of the domestic HER2 diagnostic ecosystem, including HER2 low.

About AimedBio

Founded in 2018 as a spin-off from Samsung Medical Center, AimedBio is a partnered clinical-stage biotech advancing an out-licensed ADC currently in a clinical trial. The company specializes in antibody-drug conjugates (ADCs) and antibody-based cancer therapies, distinguished by its integration of patient-derived data and samples throughout the development process to enhance precision and clinical relevance. By working closely with clinicians, AimedBio focuses on high-priority medical needs and leverages both clinical and public data to identify effective gene targets. Its proprietary antibody panning method with patient-derived cells (PDCs) enhances ADC precision, reduces trial attrition, and improves predictions of drug efficacy and safety—thereby accelerating development timelines.

About AIVIS

AIVIS is a South Korea-based medical AI company driving innovation in digital pathology. Its flagship solution, Qanti IHC, provides automated quantification of key biomarkers—including ER, PR, HER2, and Ki-67—with exceptional capability in detecting HER2-low and ultralow cases. Backed by MFDS approval and a growing global presence, AIVIS is dedicated to advancing diagnostic accuracy and enabling AI-powered precision medicine worldwide.